New FDA Requirement to Support Labeling on DDIs in the Pediatric Population
The effects of drug-drug interactions (DDIs) could differ in the pediatric population compared to adults.…
Certara2022 年 12 月 21 日
The Phoenix Workflow Shortcuts Every Pharmacokineticist Needs
Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform can revolutionize your pharmaceutical organization’s approach to PK/PD…
Certara2022 年 12 月 16 日
Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors
Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity…
Certara2022 年 12 月 8 日
Therapeutic Proteins’ Drug-Drug Interactions: Updates & Challenges
Therapeutic proteins (TP) - and more specifically monoclonal antibodies - are part of the therapeutic…
Certara2022 年 12 月 5 日
Project Optimus: How to Prepare for Success
For some time now, cancer drug developers have known “Project Optimus” and new dose optimization…
Certara2022 年 11 月 28 日
The eCTD Submission Process: Tips and Tricks for Drug Development Success
Our experts compiled the tips and best practices you need to know for a successful…
Certara2022 年 11 月 22 日
Tips & Tricks for Data Management in Phoenix WinNonlin
Learn some tips & tricks for the Data Wizard, a data management tool in Phoenix,…
Certara2022 年 11 月 18 日
Tips to Use Phoenix WinNonlin More Efficiently
Certara’s Phoenix™ Pharmacokinetic and Pharmacodynamic (PK/PD) Platform is the single, interoperable hub for sharing pre-clinical…
Certara2022 年 11 月 7 日
The Role of PBPK Modeling & Simulation in Infants & Neonates
Many factors make it challenging to obtain adequate pediatric samples for use in drug development…
Certara2022 年 11 月 4 日
